Refractory Metastatic Colorectal CancerPhase 2DEL-LIVERNCT06607458
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
A Phase 2 study testing Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab and Trifluridine-tipiracil plus Bevacizumab Alone in people with Refractory Metastatic Colorectal Cancer, run by Delcath Systems Inc. at 20 sites in 9 countries.
Trial summary
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and tolerable. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Refractory Metastatic Colorectal Cancer
- What is being tested?
- Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab and Trifluridine-tipiracil plus Bevacizumab Alone
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 20 sitesin 9 countries
- Study dates
- 5 Aug 2025to Oct 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically confirmed diagnosis of metastatic colorectal cancer and histologically or cytologically proven CRC metastases that occupy 50% or less of the liver parenchyma.
- Patient has liver-dominant metastatic disease. Liver-dominant is defined as the majority of total tumor burden is located in the liver, and the liver lesions are not resectable or treatable with ablation or are associated with extrahepatic disease that makes surgical intervention non-curative.
- Disease in the liver must be measurable (per RECIST v.1.1 guidelines) by computed tomography (CT) and/or magnetic resonance imaging (MRI).
- If there is evidence of extrahepatic metastatic disease, it is limited, and the life-threatening component of disease is in the liver. Limited extrahepatic disease is defined in this protocol as follows: up to 5 tumor lesions in the lung with longest diameter not greater than 2 cm and/or up to 5 lymph nodes that measure 2 cm or less per lesion; solitary lesions definitively treated with no sign of progression in the last 6 months.
- Scans used to determine eligibility (CT scan of the chest/abdomen/pelvis and MRI of the liver) must be performed within 28 days prior to randomization.
- Previous treatment and progressed on or following, or intolerant to, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and/or an anti-EGFR therapy if RAS wild-type.
- ECOG PS of 0-1 within 14 days prior to randomization.
Who cannot join
- Child-Pugh Class B or C cirrhosis or evidence of clinically significant portal hypertension by history, endoscopy, or radiologic studies (large abdominal varices, prior history of varices by endoscopy).
- New York Heart Association functional classification II, III or IV or active cardiac condition(s), including unstable coronary syndromes (unstable or severe angina, recent myocardial infarction), worsening or new-onset congestive heart failure, significant arrhythmias, or severe valvular disease that create(s) undue risks of undergoing general anesthesia.
- History or evidence of clinically significant pulmonary disease that precludes the use of general anesthesia.
- History of bleeding disorders, presence of brain metastases, or other intracranial abnormalities found on baseline radiologic imaging that would put them at risk for bleeding with anti-coagulation.
- Known varices at risk of bleeding, including medium or large esophageal or gastric varices, active peptic ulcer, or history of recent hemoptysis.
- Active second malignancy, or has history of recently definitively treated invasive cancer in the past 2 years prior to enrolment with the exception of non-melanoma skin cancer.
Show all 24Show fewer
- Peritoneal lesions or large abdominal masses.
- Use of immunosuppressive drugs.
- Inability to temporarily stop chronic anti-coagulation therapy.
- Active bacterial infections with systemic manifestations.
- Active viral infection, including Hepatitis B and Hepatitis C infection. NOTE: Patients with anti-hepatitis B core antibody (HBc) positive, or hepatitis B surface antigen (HBsAg) but DNA negative are allowed exception(s).
- Severe allergic reaction to iodine contrast that cannot be controlled by premedication with antihistamines and steroids.
- History of or known hypersensitivity to melphalan or the components of the melphalan/HDS system.
- History of known hypersensitivity to heparin or the presence of heparin-induced thrombocytopenia.
- Uncontrolled endocrine disorder including diabetes mellitus, hypothyroidism, or hyperthyroidism.
- Received anti-cancer therapy including radiotherapy or investigational agent for any indication ≤ 30 days prior to randomization
- Previous treatment with trifluridine-tipiracil.
- History of allergic reactions attributed to compounds of similar composition to trifluridine/tipiracil or any of its excipients.
- Hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption.
- History of allergic reactions or hypersensitivity to bevacizumab or any of its excipients.
- History of hypersensitivity to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies.
- Contraindications to bevacizumab, including uncontrolled hypertension, history of active fistula or bowel perforation (unless in the setting of a resected primary), history of CVA or arterial thrombotic event in the last 1 year, or history of venous thrombotic event in the last 30 days.
- Evidence of hepatic vein or portal vein thrombosis
- Prior chemoembolization or radioembolization to the liver or prior hepatic arterial infusion therapy
Trial locations and contacts
20 sites in 9 countries. Contact the study team or a site near you to ask about taking part.
20 sites in 9 countries
United States9 sites, 9 recruiting
- Recruiting
University of North Carolina
Chapel Hill, North Carolina, 27514
- Recruiting
Northwestern University - Feinberg School of Medicine
Chicago, Illinois, 60611
- Recruiting
City of Hope
Duarte, California, 91010
- Recruiting
Sylvester Comprehensive Cancer Center, University of Miami Hospital
Miami, Florida, 33136
- Recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121
- Recruiting
The University of Kansas Clinical Research Center
Overland Park, Kansas, 66210
- Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, 84112
- Recruiting
UCLA Hematology/Oncology-Santa Monica
Santa Monica, California, 90404
- Recruiting
Moffitt Cancer Center
Tampa, Florida, 33612
Germany3 sites, 3 recruiting
- Recruiting
Asklepios Klinik Altona
Hamburg, 22763
- Recruiting
Medizinische Hochschule Hannover
Hanover, 30625
- Recruiting
Helios Park-Klinikum Leipzig
Leipzig, 04289
Turkey (Türkiye)2 sites, 2 recruiting
- Recruiting
Ulus Liv Hospital
Istanbul
- Recruiting
Izmir Ekonomi
Izmir, 35575
Czechia1 site, 1 recruiting
- Recruiting
Czech Republic - University Hospital
Prague, 128 08
Netherlands1 site, 1 recruiting
- Recruiting
Leiden University Medical Center (LUMC)
Leiden, 2333
Serbia1 site, 1 recruiting
- Recruiting
Clinical Hospital Center "Bezanijska Kosa"
Belgrade, 11080
United Kingdom1 site, 1 recruiting
- Recruiting
Southampton General Hospital
Southampton, SO16 6YD
About this study
Official title: An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment With Melphalan/HDS Followed by Consolidation Treatment With Trifluridine-Tipiracil Plus Bevacizumab Versus Trifluridine-Tipiracil Plus Bevacizumab Alone in Patients With Refractory Metastatic Colorectal Cancer With Liver Dominant Disease
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and tolerable. The clinical trial will also learn if the liver-directed therapy with high dose chemotherapy works on the disease in the liver. Investigators will compare the use of the liver-directed therapy with high dose chemotherapy followed by approved cancer treatment or approved cancer treatment alone.
Participants will:
- Undergo up to two liver-directed therapy with high dose chemotherapy procedures followed by approved cancer treatment or take approved cancer treatment alone
- Visit clinic at least every two weeks for checkups and tests
- Complete scans approximately every two months
Read the detailed description
This is an open-label, randomized, multi-center study in which patients with liver dominant refractory mCRC will be randomized 2:1 to receive melphalan/HDS (2 cycles) followed by trifluridine-tipiracil plus bevacizumab treatment (Arm A) or trifluridine-tipiracil plus bevacizumab alone (Arm B).
Approximately 90 patients will be randomized 2:1 to the two treatment arms (Arm A, n=60; Arm B, n=30). Patients will receive one of the following treatments within 14 days of randomization:
- Arm A: Patients will be treated with melphalan/HDS 3.0 mg/kg ideal body weight (IBW) for two treatment cycles. The second melphalan/HDS treatment will be administered 6 weeks after the first treatment with an acceptable delay of up to 2 weeks (8 weeks total) to allow for recovery of melphalan-related toxicity, if needed. Tumor response will be assessed prior to Cycle 2 of melphalan/HDS (6 to 8 weeks after Cycle 1 melphalan/HDS treatment), at the end of Week 16 (+/- 7 days), and every 8 weeks (+/- 7 days) thereafter during trifluridine-tipiracil plus bevacizumab treatment.
- Arm B: Patients will be treated with standard regimen of trifluridine-tipiracil and bevacizumab.
In both treatment arms, treatment with trifluridine-tipiracil plus bevacizumab will continue until disease progression, death, intolerable adverse events, consent withdrawal, principal investigator decision, or termination of study by Sponsor.
Cross-over: There will be no cross-over between the two arms of the study. Efficacy and Safety Assessment: Evaluation of tumor response will be determined by the local principal investigator using RECIST 1.1 criteria. Tumor response evaluation and patient management will be according to the principal investigator assessment of images and patients' clinical needs. Patients with progressive disease (PD) will be discontinued from study treatment and will be followed for survival until withdrawal of consent or death.
Study treatment will be discontinued if recovery from treatment related toxicity requires more than 2 weeks from the end of the treatment cycle during melphalan/HDS cycles (Arm A only), or more than a 28-day delay in the start of the next cycle of trifluridine-tipiracil plus bevacizumab; the end of treatment (EOT) visit will be conducted at that time or within 4 weeks.
Safety will be monitored continuously by documentation of AEs, SAEs, clinical laboratory measurements, vital signs, and physical examination.
Data Safety Monitoring Board (DSMB): A DSMB including independent (non-investigator) clinicians will oversee the emerging patient safety profile during the study. The DSMB will review study data on a regular basis according to the DSMB Charter.
- Conditions
- Refractory Metastatic Colorectal Cancer
- Being tested
- Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone
- Keywords
- melphalan/HDS, melphalan/hepatic delivery system, trifluridine-tipiracil, trifluridine-tipiracil (FTD-TPI), trifluridine-tipiracil (FTD-TPI) plus bevacizumab, trifluridine-tipiracil plus bevacizumab, hepatic delivery system, melphalan, liver dominant disease, colorectal cancer, metastatic colorectal cancer, refractory metastatic colorectal cancer, rectal cancer
- Medical subject headings
- Colorectal Neoplasms, Rectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus BevacizumabDrug
Also called Melphalan, HDS, Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil
Trifluridine-tipiracil plus Bevacizumab Alone
Trifluridine-tipiracil plus Bevacizumab AloneDrug
Also called Trifluridine-tipiracil, Bevacizumab
Trifluridine-tipiracil plus Bevacizumab Alone
| Study group | Role | What they receive |
|---|---|---|
| Melphalan/HDS followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab | Experimental | Melphalan/HDS is given as an infusion of Melphalan into the hepatic artery under general anesthesia. This treatment is administered twice, 8 weeks apart. Following 2 treatments with Melphalan/HDS, Trifluridine-tipiracil is given 35 mg/m2 up to a maximum of 80 mg per dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle; and intravenous (IV) bevacizumab 5 mg/kg body weight on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity Receives: Drug: Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab |
| Trifluridine-tipiracil plus Bevacizumab Alone | Active comparator | Trifluridine-tipiracil plus Bevacizumab is the standard of care for patients with metastatic colorectal cancer. Trifluridine-tipiracil is given 35 mg/m2 up to a maximum of 80 mg per dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle; and intravenous (IV) bevacizumab 5 mg/kg body weight on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity Receives: Drug: Trifluridine-tipiracil plus Bevacizumab Alone |
What is being measured
The primary outcome is the main question the study is designed to answer.
hPFS
Hepatic Progression Free Survival
Measured: time from randomization to the first occurrence of hepatic disease progression, assessed over 24 months
Secondary outcomes (8)
PFS
Progression Free Survival
Measured: time from randomization to the first occurrence of progression, assessed up to 24 months
OS
Overall Survival
Measured: time from randomization date to the date of death due to any cause, assessed up to 36 months
ORR
Overall Response Rate complete response [CR] + partial response [PR]
Measured: Baseline through completion of treatment, assessed up to 24 months
hORR
Hepatic Overall Response Rate
Measured: assessed from Baseline until there is evidence of disease progression in the liver, assessed up to 24 months
DOR
Duration of Response
Measured: assessed from Baseline until there is evidence of disease progression, assessed up to 24 months
DCR
Disease Control Rate
Measured: complete response of any duration, partial response of any duration, or stable disease for a minimum of 12 weeks from randomization date, assessed up to 24 months
hDOR
Hepatic Duration of Response
Measured: assessed from Baseline until there is evidence of hepatic disease progression, assessed up to 24 months
hDCR
Hepatic Disease Control Rate
Measured: complete hepatic response of any duration, partial response of any duration, or stable disease for a minimum of 12 weeks from randomization date, assessed up to 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2024
- Study start5 Aug 2025
- Primary completionDec 2026 (estimated)
- Study completionOct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Refractory Metastatic Colorectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Delcath Systems Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Marwan Fakih, MD, Principal investigator, City of Hope Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06607458
- Sponsor's protocol ID
- PHP-CRC-201
- Acronym
- DEL-LIVER
- Status last verified
- Oct 2026
- First submitted
- 14 Sep 2024
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Delcath does not currently have a plan to share IPD
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment With Melphalan/HDS Followed by Consolidation Treatment With Trifluridine-Tipiracil Plus Bevacizumab Versus Trifluridine-Tipiracil Plus Bevacizumab Alone in Patients With Refractory Metastatic Colorectal Cancer With Liver Dominant Disease
- ClinicalTrials.gov ID
- NCT06607458
- Acronym / sponsor ID
- DEL-LIVER / PHP-CRC-201
- Conditions
- Refractory Metastatic Colorectal Cancer
- Keywords
- melphalan/HDS, melphalan/hepatic delivery system, trifluridine-tipiracil, trifluridine-tipiracil (FTD-TPI), trifluridine-tipiracil (FTD-TPI) plus bevacizumab, trifluridine-tipiracil plus bevacizumab, hepatic delivery system, melphalan
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Delcath Systems Inc.Industry (pharma, biotech, devices)
- Study start
- 5 Aug 2025 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Oct 2027 (estimated)
- First posted
- 23 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and tolerable. The clinical trial will also learn if the liver-directed therapy with high dose chemotherapy works on the disease in the liver. Investigators will compare the use of the liver-directed therapy with high dose chemotherapy followed by approved cancer treatment or approved cancer treatment alone.
Participants will:
- Undergo up to two liver-directed therapy with high dose chemotherapy procedures followed by approved cancer treatment or take approved cancer treatment alone
- Visit clinic at least every two weeks for checkups and tests
- Complete scans approximately every two months
Detailed description
This is an open-label, randomized, multi-center study in which patients with liver dominant refractory mCRC will be randomized 2:1 to receive melphalan/HDS (2 cycles) followed by trifluridine-tipiracil plus bevacizumab treatment (Arm A) or trifluridine-tipiracil plus bevacizumab alone (Arm B).
Approximately 90 patients will be randomized 2:1 to the two treatment arms (Arm A, n=60; Arm B, n=30). Patients will receive one of the following treatments within 14 days of randomization:
- Arm A: Patients will be treated with melphalan/HDS 3.0 mg/kg ideal body weight (IBW) for two treatment cycles. The second melphalan/HDS treatment will be administered 6 weeks after the first treatment with an acceptable delay of up to 2 weeks (8 weeks total) to allow for recovery of melphalan-related toxicity, if needed. Tumor response will be assessed prior to Cycle 2 of melphalan/HDS (6 to 8 weeks after Cycle 1 melphalan/HDS treatment), at the end of Week 16 (+/- 7 days), and every 8 weeks (+/- 7 days) thereafter during trifluridine-tipiracil plus bevacizumab treatment.
- Arm B: Patients will be treated with standard regimen of trifluridine-tipiracil and bevacizumab.
In both treatment arms, treatment with trifluridine-tipiracil plus bevacizumab will continue until disease progression, death, intolerable adverse events, consent withdrawal, principal investigator decision, or termination of study by Sponsor.
Cross-over: There will be no cross-over between the two arms of the study. Efficacy and Safety Assessment: Evaluation of tumor response will be determined by the local principal investigator using RECIST 1.1 criteria. Tumor response evaluation and patient management will be according to the principal investigator assessment of images and patients' clinical needs. Patients with progressive disease (PD) will be discontinued from study treatment and will be followed for survival until withdrawal of consent or death.
Study treatment will be discontinued if recovery from treatment related toxicity requires more than 2 weeks from the end of the treatment cycle during melphalan/HDS cycles (Arm A only), or more than a 28-day delay in the start of the next cycle of trifluridine-tipiracil plus bevacizumab; the end of treatment (EOT) visit will be conducted at that time or within 4 weeks.
Safety will be monitored continuously by documentation of AEs, SAEs, clinical laboratory measurements, vital signs, and physical examination.
Data Safety Monitoring Board (DSMB): A DSMB including independent (non-investigator) clinicians will oversee the emerging patient safety profile during the study. The DSMB will review study data on a regular basis according to the DSMB Charter.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Melphalan/HDS followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab | Experimental | Drug: Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus BevacizumabMelphalan/HDS is given as an infusion of Melphalan into the hepatic artery under general anesthesia. This treatment is administered twice, 8 weeks apart. Following 2 treatments with Melphalan/HDS, Trifluridine-tipiracil is given 35 mg/m2 up to a maximum of 80 mg per dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle; and intravenous (IV) bevacizumab 5 mg/kg body weight on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity |
| Trifluridine-tipiracil plus Bevacizumab Alone | Active comparator | Drug: Trifluridine-tipiracil plus Bevacizumab AloneTrifluridine-tipiracil plus Bevacizumab is the standard of care for patients with metastatic colorectal cancer. Trifluridine-tipiracil is given 35 mg/m2 up to a maximum of 80 mg per dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle; and intravenous (IV) bevacizumab 5 mg/kg body weight on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Histologically confirmed diagnosis of metastatic colorectal cancer and histologically or cytologically proven CRC metastases that occupy 50% or less of the liver parenchyma.
- Patient has liver-dominant metastatic disease. Liver-dominant is defined as the majority of total tumor burden is located in the liver, and the liver lesions are not resectable or treatable with ablation or are associated with extrahepatic disease that makes surgical intervention non-curative.
- Disease in the liver must be measurable (per RECIST v.1.1 guidelines) by computed tomography (CT) and/or magnetic resonance imaging (MRI).
- If there is evidence of extrahepatic metastatic disease, it is limited, and the life-threatening component of disease is in the liver. Limited extrahepatic disease is defined in this protocol as follows: up to 5 tumor lesions in the lung with longest diameter not greater than 2 cm and/or up to 5 lymph nodes that measure 2 cm or less per lesion; solitary lesions definitively treated with no sign of progression in the last 6 months.
- Scans used to determine eligibility (CT scan of the chest/abdomen/pelvis and MRI of the liver) must be performed within 28 days prior to randomization.
Key exclusion criteria (24 listed)
- Child-Pugh Class B or C cirrhosis or evidence of clinically significant portal hypertension by history, endoscopy, or radiologic studies (large abdominal varices, prior history of varices by endoscopy).
- New York Heart Association functional classification II, III or IV or active cardiac condition(s), including unstable coronary syndromes (unstable or severe angina, recent myocardial infarction), worsening or new-onset congestive heart failure, significant arrhythmias, or severe valvular disease that create(s) undue risks of undergoing general anesthesia.
- History or evidence of clinically significant pulmonary disease that precludes the use of general anesthesia.
- History of bleeding disorders, presence of brain metastases, or other intracranial abnormalities found on baseline radiologic imaging that would put them at risk for bleeding with anti-coagulation.
- Known varices at risk of bleeding, including medium or large esophageal or gastric varices, active peptic ulcer, or history of recent hemoptysis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus BevacizumabAlso: Melphalan, HDS, Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracilTrifluridine-tipiracil plus Bevacizumab Alone | Drug | Melphalan/HDS followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab |
| Trifluridine-tipiracil plus Bevacizumab AloneAlso: Trifluridine-tipiracil, BevacizumabTrifluridine-tipiracil plus Bevacizumab Alone | Drug | Trifluridine-tipiracil plus Bevacizumab Alone |
Primary outcome
hPFS
Time frame: time from randomization to the first occurrence of hepatic disease progression, assessed over 24 months
Hepatic Progression Free Survival
8 secondary outcomes
PFS
Time frame: time from randomization to the first occurrence of progression, assessed up to 24 months
OS
Time frame: time from randomization date to the date of death due to any cause, assessed up to 36 months
ORR
Time frame: Baseline through completion of treatment, assessed up to 24 months
hORR
Time frame: assessed from Baseline until there is evidence of disease progression in the liver, assessed up to 24 months
DOR
Time frame: assessed from Baseline until there is evidence of disease progression, assessed up to 24 months
DCR
Time frame: complete response of any duration, partial response of any duration, or stable disease for a minimum of 12 weeks from randomization date, assessed up to 24 months
hDOR
Time frame: assessed from Baseline until there is evidence of hepatic disease progression, assessed up to 24 months
hDCR
Time frame: complete hepatic response of any duration, partial response of any duration, or stable disease for a minimum of 12 weeks from randomization date, assessed up to 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Individual participant dataSharing planned: No. Delcath does not currently have a plan to share IPD
Related trials for Refractory Metastatic Colorectal Cancer
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
RecruitingPhase 1
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Solid Tumor, Adult, Metastatic Solid Tumor
Active, not recruitingPhase 2
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma
Not yet recruitingPhase 3
GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer
Colorectal Cancer
RecruitingPhase 1
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marwan Fakih, MD principal investigator
City of Hope Medical Center
20 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab and Trifluridine-tipiracil plus Bevacizumab Alone in people with Refractory Metastatic Colorectal Cancer, run by Delcath Systems Inc. at 20 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in United States, Germany, Turkey (Türkiye), Czechia, Italy and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Matthew Cooney, MD (216-374-8221, MedicalMonitoring@delcath.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
hPFS (time frame: time from randomization to the first occurrence of hepatic disease progression, assessed over 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.